| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 12, 2023 | The Top Public Relations Agencies in the US for 2023: Who's Making Waves? | Noah Miller, Tech Times 12 May 2023, 12:05 pm
(Photo : Carlos Muza on Unsplash)
Trying to find a PR firm to work with for your growing business can be difficult. There are thousands of firms, many of whom offer the same thing, which makes i... |
| May 3, 2023 | 5 Reasons To Attend A Tech Conference And 5 Tips To Make It Count | Nikita Sachdev, the founder & CEO of the award-winning Luna PR transforming communications in the Web3 and emerging tech landscapes. |
| Nov 23, 2022 | World Blockchain Summit brings 2022 to a close in Bangkok this December | The 23rd global edition explores the convergence of world-class content from the industry's leading experts, entrepreneurs, and investors with the opportunity to find out about the latest trends within the scope of blockchain, crypto and we... |
| Oct 5, 2022 | South Africa Plunged Into Darkness as Energy Provider Faces Concerns About Nationwide Blackouts | Klerksdorp, South Africa, Oct. 05, 2022 (GLOBE NEWSWIRE) -- For years, South Africa has been in the midst of a difficult situation. The country has been facing multiple total blackouts and energy shortages, resulting in a shrinking economy ... |
| Sep 28, 2022 | Jeremy Ryan's New Collection Super Gremlin Takes Over the ETH Blockchain | California, Sept. 28, 2022 (GLOBE NEWSWIRE) -- The crypto and web3 veteran, NFT Demon, is making waves in the industry with his new NFT collection titled Super Gremlin. The artist's most recent project is set to hit the metaverse via Decent... |
| Aug 23, 2022 | Ellie Burnett Launches Inclusive NFT Collection, Rad Rabbits | LOS ANGELES, CA / ACCESSWIRE / August 23, 2022 / Ellie Burnett is the founder and entrepreneur behind the Rad Rabbits collective, an NFT project that features 111 unique 1:1 NFTs, released on the 11th of each month. Each Rabbit is a unique ... |
| Aug 21, 2022 | Source Protocol & EonXI Lab Launch Joint Venture to Lead Trillion Dollar Web 3.0 Industry | TORTOLA, BRITISH VIRGIN ISLANDS / ACCESSWIRE / August 21, 2022 / United in their mission to drive mass adoption of Web 3.0 technology, Source Protocol Ltd and EonXI Lab have announced an exciting new joint venture, SourceWorld, where their ... |
| Jun 21, 2022 | Jupiter Exchange Ramps Up Hiring Despite Industry-Wide Job Cuts | NEW YORK, NY / ACCESSWIRE / June 21, 2022 / Jupiter Exchange, an alternative asset exchange that leverages fractional NFT technology, is ramping up its hiring process as the cryptocurrency industry struggles with job losses. Coming off its ... |
| Mar 8, 2022 | The First-Ever Crypto Polo Match Hits South Florida | Jessel Thomas, Tech Times 08 March 2022, 12:03 am
South Florida is gearing up to host the first-ever crypto polo match where celebrities, venture capitalists, investors, politicians, and the media will come together in the most extravagant ... |
| Feb 8, 2022 | BIOVAXYS ANNOUNCES NON-BROKERED PRIVATE PLACEMENT | VANCOUVER, BC, Feb. 8, 2022 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce a non-brokered private placement (the "Private Placement&qu... |
| Feb 8, 2022 | BIOVAXYS ANNOUNCES NON-BROKERED PRIVATE PLACEMENT | VANCOUVER, BC, Feb. 8, 2022 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys" or the "Company") is pleased to announce a non-brokered private placement (the "Private Place... |
| Sep 17, 2021 | BioVaxys Cancer Vaccine Manufacturing Partner Bio Elpida Reaches Bioproduction Milestone | VANCOUVER, British Columbia, Sept. 17, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), announced today that cancer vaccine manufacturing partner Bio Elpida in Lyon, France, has re... |
| Sep 14, 2021 | BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH Programs | VANCOUVER, BC, Sept. 14, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), announced today that global CDMO partner WuXi Biologics, has completed the synthesis of recombinant SARS-C... |
| Sep 7, 2021 | Further Study in humans shows that the DTH response, the basis for CoviDTH, is highly durable and persists for at least one year after COVID-19 exposure or vaccine administration | VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Sept. 7, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that the Scientific ... |
| Aug 3, 2021 | Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans | Yvelise Barrios, MD, PhD, Immunologist and leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behind CoviDTH, joins BioVaxys as scientific adviser
VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUN... |
| Jul 22, 2021 | FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH | VANCOUVER, British Columbia, July 22, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTCQB: BVAXF) ("BioVaxys"), is pleased to announce today that the US Food and Drug Administration ("FDA") has pr... |
| Jun 29, 2021 | BioVaxys Announces Non-Brokered Private Placement | VANCOUVER, BC, June 29, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) ("BioVaxys" or the "Company") is pleased to announce a non-brokered private placement (the "Private Placement&... |
| Jun 29, 2021 | BioVaxys Technology : Announces Non-Brokered Private Placement | VANCOUVER, BC, June 28, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA:5LB, OTCQB:BVAXF) ("BioVaxys" or the "Company") is pleased to announce a non-brokered private placement (the "Private Placement&... |
| Jun 15, 2021 | BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development | VANCOUVER, British Columbia, June 15, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), is pleased to announce today that the US Food and Drug Administration (FDA) has reviewed its ... |
| Jun 1, 2021 | BioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine Study | VANCOUVER, BC and LYON, France, June 1, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (US OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that its bioproduction partner Bio Elpi... |
| May 24, 2021 | Biovaxys Strengthens Internal Expertise With Appointment Of Scientific Advisor For Ovarian Cancer Vaccine Clinical Program And Papilocare Marketing | VANCOUVER, British Columbia, May 24, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV, FRA: 5LB, US OTCQB: BVAXF) ("BioVaxys" or "the Company") is pleased to announce that Charles J. Dunton, MD, has joined BioVa... |
| May 20, 2021 | BioVaxys Announces Appointment of Policy Advisor | VANCOUVER, BC, May 20, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:BVAXF) ("BioVaxys"), a biotechnology company that is advancing viral and oncology vaccine platforms as well as immuno-diagnostic prod... |
| May 19, 2021 | BioVaxys Announces Uplisting To The OCTQB Venture Market | VANCOUVER, BC, May 19, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA:5LB), (OTCQB:BVAXF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, is pleased to announc... |
| May 19, 2021 | BioVaxys Announces Uplisting To The OCTQB Venture Market | VANCOUVER, BC, May 19, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, is pleased to annou... |
| May 19, 2021 | BioVaxys Announces Uplisting To The OCTQB Venture Market | VANCOUVER, BC, May 19, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV), (FRA: 5LB), (OTCQB: BVAXF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, is pleased to announce tha... |
| May 3, 2021 | BioVaxys And BioElpida Sign Definitive Exclusive Agreement To Begin Ovarian Cancer Vaccine Bioproduction | VANCOUVER, BC, May 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (CSE: BIOV.CN) (FRA: 5LB) (OTC: BVAXF) ("BioVaxys" or "Company") announced today that it has signed the definitive exclusive bioproduction ... |
| Mar 31, 2021 | BIOVAXYS files FDA pre-IND meeting request and briefing package for COVID-T | VANCOUVER, BC, March 31, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:LMNGF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced today that it... |
| Mar 31, 2021 | BIOVAXYS files FDA pre-IND meeting request and briefing package for COVID-T | VANCOUVER, BC, March 31, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA:5LB) (OTC:LMNGF) ("BioVaxys"), the world leader in haptenized antigen vaccines for antiviral and cancer applications, announced today that it is has... |
| Mar 1, 2021 | BioVaxys Expanding Technology Platform To Address Emerging SARS-CoV-2 Variants | VANCOUVER, B.C., March 1, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer applications, announced today that... |
| Mar 1, 2021 | BioVaxys Expanding Technology Platform To Address Emerging SARS-CoV-2 Variants | BVX-0320 and Covid-T to have capability to address UK, Brazilian and South African Virus Variants
VANCOUVER, B.C., March 1, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), the world... |
| Mar 1, 2021 | BioVaxys Expanding Technology Platform To Address Emerging SARS-CoV-2 Variants | VANCOUVER, B.C., March 1, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC: LMNGF) ("BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer applications, announced today that it is ... |
| Feb 10, 2021 | BioVaxys and Procare Health Announce Broad Co-Development, Joint Commercialization and Marketing Collaboration for Cancer and Viral Vaccines | VANCOUVER, BC and BARCELONA, Spain, Feb. 10, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC:L MNGF) ("BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer applications, a... |
| Feb 10, 2021 | BioVaxys and Procare Health Announce Broad Co-Development, Joint Commercialization and Marketing Collaboration for Cancer and Viral Vaccines | - USD$900,000 In-Kind Investment by Procare Health into Phase I Clinical Study for BVX-0918A in the EU
- Co-Development of Vaccines for Cervical Cancer and HPV
- Right of First Refusal for US Marketing of Papilocare™
VANCOUVER, BC and BARCE... |
| Feb 10, 2021 | BioVaxys and Procare Health Announce Broad Co-Development, Joint Commercialization and Marketing Collaboration for Cancer and Viral Vaccines | VANCOUVER, BC and BARCELONA, Spain, Feb. 10, 2021 /CNW/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTC:L MNGF) ("BioVaxys"), the world leader in haptenized protein vaccines for antiviral and cancer applications, and Proc... |
